Efficacy and safety of deuruxolitinib, an oral selective Janus kinase inhibitor, in adults with alopecia areata: Results from the Phase 3 randomized, controlled trial (THRIVE-AA1)
July 2024
in “
Journal of the American Academy of Dermatology
”
Research cited in this study
7 / 7 results
research The Burden of Alopecia Areata: A Scoping Review Focusing on Quality of Life, Mental Health, and Work Productivity
Alopecia areata greatly affects people's life quality, mental health, and work life.
research Two Phase 3 Trials of Baricitinib for Alopecia Areata
Baricitinib was effective in treating alopecia areata in two major trials.
research Alopecia Areata: Current Understanding and Management
Alopecia areata is a chronic condition causing hair loss, with new treatments targeting the immune system showing promise.
research A Comprehensive Literature Review of JAK Inhibitors in the Treatment of Alopecia Areata
JAK inhibitors show promise in effectively treating hair loss from alopecia areata.
research JAK Inhibitors for Alopecia Areata: A Systematic Review and Meta-Analysis
JAK inhibitors are effective for treating alopecia areata, with most patients seeing hair growth after treatment.
research Systemic Treatments for Alopecia Areata: A Systematic Review
No systemic treatment for alopecia areata has strong evidence of effectiveness.
research Alopecia Areata Is Driven by Cytotoxic T Lymphocytes and Is Reversed by JAK Inhibition
Alopecia areata can be reversed by JAK inhibitors, promoting hair regrowth.